Cannabis Conundrum

Cannabis as a Gateway Drug for Opioid Use Disorder

Abstract: Cannabis as a Gateway Drug for Opioid Use DisorderEmerging evidence suggests that adolescent cannabis use may biologically and behaviourally increase vulnerability to later opioid use and the development of opioid use disorder (OUD). The paper argues that while shared risk factors—such as trauma, impulsivity, psychiatric symptoms, and genetic predisposition—contribute to both cannabis and opioid […]

Cannabis as a Gateway Drug for Opioid Use Disorder Read More »

New Canadian Data Sharpen the Case Against Cannabis Smoking’s Toll on the Lungs

Rising rates of cannabis use worldwide have renewed scientific attention on a question long overshadowed by the tobacco debate: what does inhaling burnt cannabis actually do to the human airway? A newly published Canadian investigation, presented recently through the IASIC Speaker Series webinar “The Lung Health Implications of Cannabis Smoking,” moderated by Dr Russell Kamer,

New Canadian Data Sharpen the Case Against Cannabis Smoking’s Toll on the Lungs Read More »

Cannabis Rescheduling Case Ends With Warnings on Psychosis, Crime and Youth Risk

The federal marijuana rescheduling hearing has closed after twelve days of testimony. The closing witnesses left behind a sobering record. Rather than building a case for marijuana as ordinary medicine, the cannabis rescheduling case exposed a different picture. Witnesses described uncontrolled products, unresolved psychosis risk and a persistent link to organised crime. A recommendation from

Cannabis Rescheduling Case Ends With Warnings on Psychosis, Crime and Youth Risk Read More »

Commercial Cannabis Legalisation Drives Addiction and Psychosis, Global Review Finds

A major global review has linked commercial cannabis legalisation to rising rates of addiction, psychiatric hospital admissions and cannabis use disorder. Researchers at the University of Bath led the study, published in The Lancet Psychiatry. The team tracked cannabis policy changes in dozens of countries from 2000 to 2025. One number stands out immediately: cannabis

Commercial Cannabis Legalisation Drives Addiction and Psychosis, Global Review Finds Read More »

Cannabis and Mental Health: A Review

PMID: 41801216 . DOI: 10.1001/jamainternmed.2025.8215 Abstract Importance: Cannabis use is common among those with mental health conditions, and many people report using cannabis to manage mental health symptoms. It is important for clinicians to understand the lack of clear benefits of cannabis for mental health conditions and the potential for substantial adverse effects. Observations: Overall, the potential benefits of

Cannabis and Mental Health: A Review Read More »

Association of cannabis use and lung cancer: a retrospective cohort study

Received April 16, 2026; Published online April 22, 2026 DOI: 10.1016/j.lungcan.2026.109421 External Link   Highlights Individuals with cannabis use disorder had an increased risk of any lung and/or bronchus cancer in this cohort study. Increased risk for small cell carcinoma, squamous cell carcinoma, and adenocarcinoma was observed. Further studies are required to explore the strength of this

Association of cannabis use and lung cancer: a retrospective cohort study Read More »

Is Cannabis Psychosis Riskier Than Drug-Induced Psychosis?

New Yale study suggests key clinical, cognitive, and brain-based differences. Key points Modern high-potency cannabis may be changing the landscape of psychotic disorders. Cannabis psychosis may be more than a temporary drug-induced condition. Continued cannabis (THC) use may triple relapse risk despite taking antipsychotics. Daily use and high-potency THC increase psychosis risk in a dose-dependent

Is Cannabis Psychosis Riskier Than Drug-Induced Psychosis? Read More »

What the FDA Knows About CBD and Cancer: Regulatory Evidence, Expert Commentary, and Public Health Failure

 Background. Cannabidiol (CBD) now dominates consumer health markets worldwide. Manufacturers market it predominantly on the basis of perceived safety. However, CBD carcinogenicity FDA evidence, generated during the pharmaceutical approval process for purified CBD (Epidiolex, GW Research Ltd, NDA 210365), raises substantive concerns that regulators have not communicated to the public, prescribers, or policymakers. Evidence reviewed. This

What the FDA Knows About CBD and Cancer: Regulatory Evidence, Expert Commentary, and Public Health Failure Read More »

Scroll to Top